SGLT-2 Inhibitor Dapagliflozin Gets Another Chance At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will consider a new submission for AstraZeneca/Bristol-Myers Squibb’s dapagliflozin on Dec. 12. Filing includes several new studies and more long-term data.